S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:PROK

ProKidney (PROK) Stock Forecast, Price & News

$4.32
0.00 (0.00%)
(As of 09/27/2023 ET)
Compare
Today's Range
$3.95
$4.34
50-Day Range
$4.32
$13.08
52-Week Range
$3.95
$14.19
Volume
726,426 shs
Average Volume
290,645 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.60

ProKidney MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
261.1% Upside
$15.60 Price Target
Short Interest
Bearish
38.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of ProKidney in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$9.30 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.20) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

872nd out of 976 stocks

Biological Products, Except Diagnostic Industry

145th out of 159 stocks


PROK stock logo

About ProKidney (NASDAQ:PROK) Stock

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Price History

PROK Stock News Headlines

ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
ProKidney 10% Owner Trades $9.30M In Company Stock
REACT Or Retreat: ProKidney's Phase 3 Focal Point
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Major biomanufacturing project slated for Triad
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

PROK Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROK
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.60
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+261.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-108,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($42.77) per share

Miscellaneous

Free Float
129,344,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Timothy A. Bertram D.V.M. (Age 68)
    Ph.D., Founder, CEO & Director
    Comp: $970.4k
  • Dr. Deepak Jain Ph.D. (Age 69)
    Chief Operating Officer
    Comp: $768.65k
  • Mr. Todd C. Girolamo Esq. (Age 58)
    J.D., M.B.A., Chief Legal Officer & Corp. Sec.
    Comp: $600.17k
  • Mr. James Coulston CPA (Age 47)
    Chief Financial Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Sr. VP of Investor Relations
  • Ms. Mary Weger (Age 64)
    Chief People Officer
  • Ms. Ashley H. Johns
    Sr. VP & Head of Global Clinical Operations
  • Dr. Joseph M. Stavas M.D.
    M.P.H., Sr. VP and Head of Global Clinical Devel. & Interventional Procedures
  • Dr. Darin J. Weber Ph.D. (Age 55)
    Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
  • Dr. Bruce Culleton M.D.
    Exec. VP of Clinical Devel. & Commercialization













PROK Stock - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PROK shares.
View PROK analyst ratings
or view top-rated stocks.

What is ProKidney's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price targets for ProKidney's shares. Their PROK share price forecasts range from $13.00 to $18.00. On average, they anticipate the company's share price to reach $15.60 in the next year. This suggests a possible upside of 261.1% from the stock's current price.
View analysts price targets for PROK
or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2023?

ProKidney's stock was trading at $6.86 at the beginning of the year. Since then, PROK shares have decreased by 37.0% and is now trading at $4.32.
View the best growth stocks for 2023 here
.

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PROK earnings forecast
.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.27.

What ETF holds ProKidney's stock ?

ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

What is ProKidney's stock symbol?

ProKidney trades on the NASDAQ under the ticker symbol "PROK."

Who are ProKidney's major shareholders?

ProKidney's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.41%), State Street Corp (0.42%), Geode Capital Management LLC (0.32%), Northern Trust Corp (0.19%), Nuveen Asset Management LLC (0.09%) and Nuveen Asset Management LLC (0.09%).
View institutional ownership trends
.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProKidney's stock price today?

One share of PROK stock can currently be purchased for approximately $4.32.

How much money does ProKidney make?

ProKidney (NASDAQ:PROK) has a market capitalization of $1.02 billion. The company earns $-108,030,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How can I contact ProKidney?

ProKidney's mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The official website for the company is www.prokidney.com. The company can be reached via phone at 336-999-7028 or via email at lroth@burnsmc.com.

This page (NASDAQ:PROK) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -